Donor cell leukemia: Is reappearance of gene mutations in donor cells more than an incidental phenomenon?

Tal Shahar Gabay; Noa Chapal-Ilani; Yoni Moskovitz; Tamir Biezuner; Barak Oron; Yardena Brilon; Anna Fridman-Dror; Rawan Sabah; Ran Balicer; Amos Tanay; Netta Mendelson-Cohen; Eldad J. Dann; Riva Fineman; Nathali Kaushansky; Shlomit Yehudai-Reshef; Tsila Zuckerman; Liran I. Shlush

doi:10.3324/haematol.2019.242347

Donor cell leukemia: Is reappearance of gene mutations in donor cells more than an incidental phenomenon?

Tal Shahar Gabay, Noa Chapal-Ilani, Yoni Moskovitz, Tamir Biezuner, Barak Oron, Yardena Brilon, Anna Fridman-Dror, Rawan Sabah, Ran Balicer, Amos Tanay, Netta Mendelson-Cohen, Eldad J. Dann, Riva Fineman, Nathali Kaushansky, Shlomit Yehudai-Reshef, Tsila Zuckerman, Liran I. Shlush

Weizmann Institute of Science, Technion - Israel Institute of Technology

Research output: Contribution to journal › Letter › peer-review

Abstract

Acute myeloid leukemia (AML) is one of the extreme outcomes of age-related clonal hematopoiesis (ARCH)1. With aging, mutations accumulate in hematopoietic stem and progenitor cells (HSPCs)2,3. Based on the estimated number of HSPCs (~50,000) in the human body and the number of somatic mutations in adult single cells (~1000)4, it is predicted that every ~100 nucleotides, a somatic mutation will occur at a low variant allele frequency (VAF).

Original language	English
Pages (from-to)	2861-2863
Number of pages	3
Journal	Haematologica
Volume	105
Issue number	12
Early online date	7 May 2020
DOIs	https://doi.org/10.3324/haematol.2019.242347
State	Published - 1 Dec 2020

All Science Journal Classification (ASJC) codes

Hematology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.3324/haematol.2019.242347

Cite this

Gabay, T. S., Chapal-Ilani, N., Moskovitz, Y., Biezuner, T., Oron, B., Brilon, Y., Fridman-Dror, A., Sabah, R., Balicer, R., Tanay, A., Mendelson-Cohen, N., Dann, E. J., Fineman, R., Kaushansky, N., Yehudai-Reshef, S., Zuckerman, T., & Shlush, L. I. (2020). Donor cell leukemia: Is reappearance of gene mutations in donor cells more than an incidental phenomenon? Haematologica, 105(12), 2861-2863. https://doi.org/10.3324/haematol.2019.242347

@article{6763d162aff54dffb18f0e76b595532f,

title = "Donor cell leukemia: Is reappearance of gene mutations in donor cells more than an incidental phenomenon?",

abstract = "Acute myeloid leukemia (AML) is one of the extreme outcomes of age-related clonal hematopoiesis (ARCH)1. With aging, mutations accumulate in hematopoietic stem and progenitor cells (HSPCs)2,3. Based on the estimated number of HSPCs (\textasciitilde{}50,000) in the human body and the number of somatic mutations in adult single cells (\textasciitilde{}1000)4, it is predicted that every \textasciitilde{}100 nucleotides, a somatic mutation will occur at a low variant allele frequency (VAF).",

author = "Gabay, \{Tal Shahar\} and Noa Chapal-Ilani and Yoni Moskovitz and Tamir Biezuner and Barak Oron and Yardena Brilon and Anna Fridman-Dror and Rawan Sabah and Ran Balicer and Amos Tanay and Netta Mendelson-Cohen and Dann, \{Eldad J.\} and Riva Fineman and Nathali Kaushansky and Shlomit Yehudai-Reshef and Tsila Zuckerman and Shlush, \{Liran I.\}",

note = "Funding Information: 1Hematology Research Center, Rambam Health Care Campus, Haifa; 2Bruce Rappaport Faculty of Medicine, Technion, Haifa; 3Department of Immunology, Weizmann Institute of Science, Rehovot; 4Clalit Research Institute, Tel Aviv; 5Department of Computer Science and Applied Mathematics, Weizmann Institute of Science, Rehovot and 6Department of Hematology and BMT, Rambam Health Care Campus, Haifa, Israel \#SY-R, TZ and LIS contributed equally as co-senior authors. Correspondence: TSILA ZUCKERMAN - t\[email protected] doi:10.3324/haematol.2019.242347 Funding: this work was supported by the Israel Cancer Association through grants n. 20170179 and 20181136.",

year = "2020",

month = dec,

day = "1",

doi = "10.3324/haematol.2019.242347",

language = "الإنجليزيّة",

volume = "105",

pages = "2861--2863",

journal = "Haematologica",

issn = "0390-6078",

publisher = "Ferrata Storti Foundation",

number = "12",

}

Gabay, TS, Chapal-Ilani, N, Moskovitz, Y, Biezuner, T, Oron, B, Brilon, Y, Fridman-Dror, A, Sabah, R, Balicer, R, Tanay, A, Mendelson-Cohen, N, Dann, EJ, Fineman, R, Kaushansky, N, Yehudai-Reshef, S, Zuckerman, T & Shlush, LI 2020, 'Donor cell leukemia: Is reappearance of gene mutations in donor cells more than an incidental phenomenon?', Haematologica, vol. 105, no. 12, pp. 2861-2863. https://doi.org/10.3324/haematol.2019.242347

TY - JOUR

T1 - Donor cell leukemia

T2 - Is reappearance of gene mutations in donor cells more than an incidental phenomenon?

AU - Gabay, Tal Shahar

AU - Chapal-Ilani, Noa

AU - Moskovitz, Yoni

AU - Biezuner, Tamir

AU - Oron, Barak

AU - Brilon, Yardena

AU - Fridman-Dror, Anna

AU - Sabah, Rawan

AU - Balicer, Ran

AU - Tanay, Amos

AU - Mendelson-Cohen, Netta

AU - Dann, Eldad J.

AU - Fineman, Riva

AU - Kaushansky, Nathali

AU - Yehudai-Reshef, Shlomit

AU - Zuckerman, Tsila

AU - Shlush, Liran I.

N1 - Funding Information: 1Hematology Research Center, Rambam Health Care Campus, Haifa; 2Bruce Rappaport Faculty of Medicine, Technion, Haifa; 3Department of Immunology, Weizmann Institute of Science, Rehovot; 4Clalit Research Institute, Tel Aviv; 5Department of Computer Science and Applied Mathematics, Weizmann Institute of Science, Rehovot and 6Department of Hematology and BMT, Rambam Health Care Campus, Haifa, Israel #SY-R, TZ and LIS contributed equally as co-senior authors. Correspondence: TSILA ZUCKERMAN - [email protected] doi:10.3324/haematol.2019.242347 Funding: this work was supported by the Israel Cancer Association through grants n. 20170179 and 20181136.

PY - 2020/12/1

Y1 - 2020/12/1

N2 - Acute myeloid leukemia (AML) is one of the extreme outcomes of age-related clonal hematopoiesis (ARCH)1. With aging, mutations accumulate in hematopoietic stem and progenitor cells (HSPCs)2,3. Based on the estimated number of HSPCs (~50,000) in the human body and the number of somatic mutations in adult single cells (~1000)4, it is predicted that every ~100 nucleotides, a somatic mutation will occur at a low variant allele frequency (VAF).

AB - Acute myeloid leukemia (AML) is one of the extreme outcomes of age-related clonal hematopoiesis (ARCH)1. With aging, mutations accumulate in hematopoietic stem and progenitor cells (HSPCs)2,3. Based on the estimated number of HSPCs (~50,000) in the human body and the number of somatic mutations in adult single cells (~1000)4, it is predicted that every ~100 nucleotides, a somatic mutation will occur at a low variant allele frequency (VAF).

UR - http://www.scopus.com/inward/record.url?scp=85097034751&partnerID=8YFLogxK

U2 - 10.3324/haematol.2019.242347

DO - 10.3324/haematol.2019.242347

M3 - رسالة

C2 - 33256388

SN - 0390-6078

VL - 105

SP - 2861

EP - 2863

JO - Haematologica

JF - Haematologica

IS - 12

ER -

Donor cell leukemia: Is reappearance of gene mutations in donor cells more than an incidental phenomenon?

Abstract

All Science Journal Classification (ASJC) codes

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this